Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Q32 Bio Inc (QTTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: QTTB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 163.12% | Avg. Invested days 69 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.69M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 1.38 - 53.79 | Updated Date 06/30/2025 |
52 Weeks Range 1.38 - 53.79 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.8% | Return on Equity (TTM) -267.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -28753506 | Price to Sales(TTM) - |
Enterprise Value -28753506 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 12197600 | Shares Floating 9771387 |
Shares Outstanding 12197600 | Shares Floating 9771387 | ||
Percent Insiders 6.57 | Percent Institutions 73.3 |
Analyst Ratings
Rating 2 | Target Price 12 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Q32 Bio Inc
Company Overview
History and Background
Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to treat complement disorders and autoimmune diseases. Founded in 2018, the company is based in Cambridge, Massachusetts.
Core Business Areas
- ADAPT Biotherapeutics: Focuses on developing therapeutics that modulate the complement system to treat autoimmune and inflammatory diseases.
Leadership and Structure
The leadership team includes key executives in R&D, clinical development, and business operations. The company's structure is typical of a biotech firm, with a focus on research, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Bemdanibeg: A fully human anti-C5aR1 antibody designed to dampen innate and adaptive immune responses and reverse tissue inflammation. Currently in clinical trials for atopic dermatitis and other inflammatory conditions. Market share is currently unavailable as the product is in clinical trials. Competitors in the atopic dermatitis space include Regeneron (REGN) and Sanofi (SNY) with Dupixent.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing significant growth, driven by innovation in areas like immunology and precision medicine. Competition is intense, and success depends on clinical trial outcomes and regulatory approvals.
Positioning
Q32 Bio Inc. is positioned as an innovator in complement-targeted therapeutics, aiming to address unmet needs in autoimmune and inflammatory diseases. Its competitive advantage lies in its novel approach to modulating the complement system.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory disease therapies is substantial, estimated to be in the billions of dollars annually. Q32 Bio Inc. is targeting specific segments within this large market, focusing on indications where its therapies may offer a unique benefit. Specific TAM figures for their target indications are unavailable in public data.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting the complement system
- Strong intellectual property position
- Experienced management team
- Clinical-stage pipeline
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risks and regulatory uncertainties
- Dependence on key programs and partnerships
Opportunities
- Expansion into new indications
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approvals
- Increasing prevalence of autoimmune and inflammatory diseases
Threats
- Competition from established therapies and companies
- Failure of clinical trials
- Adverse regulatory decisions
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- REGN
- SNY
- ALNY
- CRSP
- EDIT
Competitive Landscape
Q32 Bio Inc. faces competition from established pharmaceutical companies with larger resources and approved therapies. Its success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancement of clinical programs and fundraising activities.
Future Projections: Future growth depends on successful clinical trials and potential partnerships. Analyst projections are needed to provide specific forecasts.
Recent Initiatives: Recent initiatives include advancing Bemdanibeg through clinical trials and exploring new indications for its therapeutic platform.
Summary
Q32 Bio Inc. is a clinical-stage biotech company with a novel therapeutic approach to complement-mediated diseases. The company's success hinges on the outcome of its clinical trials, specifically for Bemdanibeg. Its current weakness is limited financial resources. Q32 needs to be successful in upcoming trails and may benefit from potential partnerships, but faces stiff competition from industry giants in the autoimmune space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (when available)
- Analyst Reports (when available)
- Industry News Sources
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Q32 Bio Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-28 | CEO & Director Ms. Jodie Pope Morrison | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.q32bio.com |
Full time employees 28 | Website https://www.q32bio.com | ||
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.